Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5185360 | 0.77 | ALDH1A1 (0.34) | IDO1TDO2ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL305225 | 0.76 | IDO1 (0.43) | IDO1TDO2ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL12164462 | 0.73 | ALDH1A1 (0.50) | ALDH1A1CYP1A2AHR | |
| SCHEMBL6891458 | 0.73 | ALDH1A1 (0.39) | IDO1TDO2ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3233743 | 0.73 | ALDH1A1 (0.32) | IDO1TDO2ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL1570072 | 0.73 | P2RX7 (0.37) | IDO1TDO2ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3376910 | 0.73 | CYP1A2 (0.39) | ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1264506 | 0.72 | — | — | |
| SCHEMBL2885020 | 0.71 | P2RX7 (0.40) | ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12164461 | 0.70 | GABRA1 (0.30) | ALDH1A1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100960-A1 | NAPHTHALENE AND QUINOLINE ANALOGS AS RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4448504-A1 | NAPHTHALENE AND QUINOLINE ANALOGS AS RXFP1 AGONISTS | Bristol-Myers Squibb Company (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-118414330-A | Naphthalene and quinoline analogs as RXFP1 agonists | 百时美施贵宝公司 | 2024-07-30 | — | — | CN | disclosed |
| WO-2023114818-A1 | NAPHTHALENE AND QUINOLINE ANALOGS AS RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-0378336-A1 | Naphthalocyanine derivatives, production thereof, optical recording medium using the same, and production thereof | Hitachi Chemical Co., Ltd. (JP) | 1990-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100960-A1 | NAPHTHALENE AND QUINOLINE ANALOGS AS RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | IDO1 374/4885TDO2 1575/4885ALDH1A1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.